PEPTIDE GUIDE

What Is Pinealon?

Pinealon is the name used for a synthetic tripeptide made from glutamic acid, aspartic acid and arginine. It is commonly abbreviated EDR from the one-letter codes for those three amino acids.

Researchers associated with the St Petersburg school of peptide bioregulation have studied Pinealon in cells, rodents and small human groups. Reported work concerns oxidative stress, gene and protein expression, neuronal survival, learning and age-related or injury-related brain dysfunction.

The human evidence is limited and difficult to assess. Reports describe small studies, often without clear randomisation, masking, placebo comparison or full adverse-event data. Pinealon has not been shown in a confirmatory clinical trial to prevent ageing, improve memory or treat Alzheimer's disease, traumatic brain injury or another neurological condition.

Research statusLimited, poorly controlled human reports; no established clinical efficacy
Compound typeSynthetic Glu-Asp-Arg tripeptide
Human evidenceSmall, limited-quality studies
ApprovalNot approved by FDA, MHRA or EMA
Last reviewedOctober 2026
THE SHORT ANSWER

Pinealon is a synthetic three-amino-acid peptide with the sequence Glu-Asp-Arg. It was developed from research on peptide fractions associated with Cortexin, an animal-tissue-derived preparation studied in Russia. Laboratory studies report effects on reactive oxygen species, cell survival, DNA interactions, gene expression and neuronal markers. Rodent experiments have examined hypoxia, prenatal stress, ageing and learning. Small Russian human reports include 72 people with long-term consequences of traumatic brain injury and another mixed study of 32 older adults, but the published descriptions do not establish the standards or reliability expected of a modern confirmatory trial. Pinealon is not an approved FDA, MHRA or EMA medicine, and its human safety, pharmacokinetics and clinical efficacy remain uncertain.

What kind of molecule is Pinealon?

Pinealon is a linear tripeptide, meaning it contains three amino-acid residues:

`Glu-Asp-Arg`

Glu is glutamic acid, Asp is aspartic acid and Arg is arginine. The abbreviation EDR uses the international one-letter code for each residue. Glutamic acid and aspartic acid carry acidic side chains, while arginine has a basic, positively charged side chain.

The name Pinealon does not mean that the peptide is a pineal hormone or that it is extracted from the pineal gland. It is also separate from Epitalon, the four-amino-acid sequence Ala-Glu-Asp-Gly. Commercial material called Pinealon may claim the same sequence, but a name alone does not verify identity, purity or formulation.

Where did Pinealon come from?

Pinealon emerged from Russian research into short peptide bioregulators led by Vladimir Khavinson and colleagues. This programme studied whether very short amino-acid sequences isolated or designed from larger tissue-derived peptide mixtures could influence organ-specific functions and ageing-related changes.

Authors describe EDR as isolated from or developed through study of Cortexin. Cortexin is a mixture of low-molecular-weight peptides produced from animal cerebral cortex tissue and used in some countries. It is not a single defined molecule, and its evidence cannot be transferred to synthetic EDR.

The exact boundary between initial isolation, sequence identification and later synthetic production is not consistently reported in accessible English-language sources. It is safer to describe Pinealon as developed during this research programme rather than assign one unsupported invention date.

What does “peptide bioregulator” mean?

Peptide bioregulator is a term used by this research school for short peptides proposed to influence gene expression, protein production and tissue function. It is not a regulatory classification such as approved medicine, biologic or dietary supplement.

Very short peptides can interact with proteins, membranes or nucleic acids under laboratory conditions. They can also be broken down into ordinary amino acids. Evidence must therefore show that an intact sequence reaches a target and produces a reproducible effect beyond providing amino-acid building blocks.

Pinealon's sequence is too short to assume brain specificity. Claims of organ-targeted regulation need direct pharmacokinetic and independent experimental support.

How was Pinealon developed?

PeriodDevelopment
Late twentieth centuryRussian researchers investigated tissue peptide extracts and proposed short regulatory sequences
2000sPinealon appeared in cell, animal and small clinical reports concerning brain function and hypoxia
2011 to 2012Studies reported oxidative-stress effects in cells and learning outcomes after prenatal hypoxia in rats
2015A 32-person Russian report examined Pinealon and Vesugen in older adults with several chronic conditions
2019 to 2021Biophysical and review papers examined EDR-DNA interaction and proposed gene-regulation mechanisms
Current positionResearch peptide with scattered human reports but no modern confirmatory clinical programme

The record differs from development through Phase I, II and III trials. Phase I usually establishes initial human safety and exposure, Phase II explores activity in a defined patient group, and Phase III confirms benefits and risks in larger controlled populations. No such Pinealon sequence is publicly established.

Can Pinealon enter cells or the nucleus?

One laboratory study attached fluorescent labels to several short peptides and observed signal in the cytoplasm, nucleus and nucleolus of HeLa cells, a human cervical-cancer cell line widely used in research. Experiments also measured interactions with short DNA sequences.

Fluorescent localisation can support cellular uptake, but the label may change a peptide's behaviour. Cancer cells in culture also differ from healthy neurons behind the blood-brain barrier.

Evidence of nuclear signal does not prove that unmodified Pinealon reaches human brain-cell nuclei after oral or systemic exposure. It also does not establish a beneficial change in gene expression.

Does Pinealon bind DNA?

Biophysical experiments have examined EDR with purified DNA using spectroscopy, nuclear magnetic resonance, viscosity measurements and computer simulation. One 2019 paper reported partial penetration of EDR into DNA's major groove and interactions involving guanine bases, influenced by magnesium ions.

The DNA major groove is a surface where proteins and small molecules can recognise base patterns. Binding in a purified system is a physical observation. It does not show which genes change in a living human brain, whether the interaction is selective, or whether it improves health.

Broad interaction with DNA could produce intended or unintended effects. Claims of genomic safety require far more than short-term binding or chromatin measurements.

What did oxidative-stress experiments show?

Reactive oxygen species, or ROS, are chemically reactive oxygen-containing molecules. Cells use some ROS in signalling, while excessive amounts can damage proteins, lipids and DNA.

A 2011 study exposed rat cerebellar granule cells, human neutrophils and PC12 cells to several oxidative-stress triggers. PC12 is a rat tumour-derived cell line used in neuronal research. Pinealon reduced ROS accumulation and some measures of cell death in a concentration-dependent pattern. It also delayed activation of ERK1/2, signalling proteins involved in cell responses and proliferation.

These results do not prove that Pinealon is an antioxidant medicine. Cell-culture concentrations, stress triggers and short measurement periods do not reproduce the metabolism or mixed pathology of a living human brain.

What are the proposed gene and protein effects?

Pinealon papers report changes involving antioxidant enzymes, apoptosis proteins and signalling pathways. Apoptosis is organised cell death. Proposed markers include superoxide dismutase 2 and glutathione peroxidase 1, enzymes that help manage oxidative stress, and caspase-3, an enzyme involved in apoptosis.

A 2020 review by researchers closely connected to the Pinealon programme proposed that EDR might interact with histones, DNA or ribonucleic acid and influence the MAPK/ERK pathway. Histones package DNA; MAPK/ERK is a chain of signals affecting cell growth, stress responses and gene expression.

Much of this model combines direct EDR experiments with broader knowledge about Alzheimer's disease pathways. A plausible connection between a marker and disease biology is not proof that Pinealon prevents or treats the disease.

What did prenatal-hypoxia research find?

Hypoxia means inadequate oxygen. Researchers exposed pregnant rats to reduced oxygen and later assessed their offspring. Pinealon was studied for effects on oxidative markers, behaviour, spatial learning and brain-cell responses.

The reported study found better performance in the Morris water maze in selected Pinealon-exposed offspring. This test measures how quickly a rodent learns the location of a hidden platform in water. Changes were also reported in cellular oxidative-stress responses.

Prenatal hypoxia in rats is a specialised developmental model. It does not establish prevention of birth injury, developmental delay or memory problems in human children. Pregnancy and developmental safety would require dedicated toxicology before any clinical inference.

What has been studied in aged animals?

Pinealon has been examined in aged rats exposed to hypoxia and hypothermia, as well as in acute hypoxia models. Reports describe behavioural, neurochemical, antioxidant-enzyme and caspase changes.

Age can alter stress responses and cell-death pathways, so including old animals is useful. However, acute low-oxygen or low-temperature stress is not equivalent to normal human cognitive ageing, Alzheimer's disease or vascular dementia.

The animal literature comes heavily from one connected research network. Independent replication using pre-registered methods, adequate group sizes and blinded outcome assessment would strengthen confidence.

Has Pinealon been studied in people with brain injury?

A later review describes a study of 72 people with long-term consequences of traumatic brain injury and cerebrasthenia. Cerebrasthenia is an older clinical term for persistent fatigue, headaches, irritability and cognitive difficulty attributed to brain dysfunction.

Pinealon was reportedly added to standard therapy, with improvements in memory tests, headaches, emotional measures and work capacity. The accessible description does not provide enough detail about random allocation, placebo control, masking, attrition or adverse-event collection to judge the result securely.

Standard therapy given at the same time makes attribution harder. Without a well-described comparison group, improvement could reflect other treatment, recovery, expectation or measurement variation.

The report is a human signal, not proof of efficacy after traumatic brain injury.

What did the 32-person ageing study report?

A 2015 Russian-language paper included 32 adults aged 41 to 83 with multiple chronic conditions and organic brain syndrome in remission. Organic brain syndrome is an older umbrella term for cognitive or behavioural change attributed to brain disease or injury.

The study examined Pinealon and Vesugen, another short peptide, and reported changes in biological-age indicators, central-nervous-system measures, oxidative signals and blood-cell markers. The abstract also reported pro-oxidant activity and reduced CD34-positive blood-cell markers, which the authors interpreted in relation to blood formation.

The small mixed population, use of more than one peptide, unclear control procedures and multiple outcomes prevent firm conclusions. A “biological age” composite is not the same as fewer illnesses, preserved independence or longer life.

This study should not be described as evidence that Pinealon slows human ageing.

Does Pinealon treat Alzheimer's disease?

No clinical trial has shown that Pinealon improves cognition or daily function in people with Alzheimer's disease. The Alzheimer's discussion comes mainly from cell models, mouse-derived neuronal cultures, pathway analysis and a review written by investigators connected to the compound.

Studies have reported preservation of selected dendritic spines in cultured neurons from disease-model mice. Dendritic spines are small projections where many synaptic connections form. Preserving their shape in culture is mechanistic evidence, not a demonstration of slower dementia.

Human Alzheimer's trials need defined diagnoses, randomisation, a placebo or active comparison, masking, adequate duration and outcomes covering cognition and daily functioning. Pinealon lacks that evidence.

Does Pinealon slow ageing?

No reliable evidence shows that Pinealon slows human ageing, extends lifespan or prevents age-related disease. Cellular stress markers, rodent behaviour and composite “biological age” measures cannot establish those outcomes.

Ageing affects many interacting systems. A compound that changes one oxidative or gene-expression marker may have no overall benefit, or could have different effects across tissues.

Is Pinealon the same as Cortexin or Epitalon?

No. Pinealon is the defined Glu-Asp-Arg tripeptide. Cortexin is a complex animal-tissue-derived peptide mixture. Epitalon is the separate tetrapeptide Ala-Glu-Asp-Gly.

Results for one cannot be assigned to another. Shared origin stories within peptide-bioregulator research do not make the materials chemically or clinically interchangeable.

How is Pinealon synthesised and characterised?

Research material can be made by solid-phase peptide synthesis from protected glutamic acid, aspartic acid and arginine building blocks. Each residue is coupled to a resin-supported chain, followed by release, removal of protecting groups and purification.

Although three residues make the sequence short, manufacturing still needs to control deletion products, incorrect order, side-chain reactions, residual protecting-group fragments and counterions. High-performance liquid chromatography can separate related substances, while mass spectrometry confirms molecular mass. Sequence methods and amino-acid analysis can provide additional identity and content information.

Licensed manufacture requires batch consistency, validated specifications and microbiological controls appropriate to the formulation. Sterility, bacterial endotoxin, particles and container compatibility are separate requirements for any sterile investigational product. A chromatographic purity claim alone does not establish clinical quality.

What is known about pharmacokinetics?

No modern published human study clearly defines Pinealon absorption, intact-peptide concentration, half-life, brain penetration, metabolism or clearance. Reports of oral administration do not by themselves show how much intact EDR entered the circulation or nervous system.

Tripeptides may be absorbed through peptide transporters, broken down into amino acids in the gut or blood, or cleared rapidly. The balance depends on chemical form and formulation. Mechanistic claims require evidence that intact EDR reaches the proposed target at a relevant concentration.

What is known about safety?

The small human reports do not provide a dependable adverse-event profile. Their accessible descriptions lack the systematic collection, comparison groups and sample sizes needed to detect uncommon or delayed harms.

The 32-person report included pro-oxidant findings and a decrease in CD34-positive blood-cell markers. These observations are not proof of clinical harm, but they argue against describing Pinealon as uniformly antioxidant or established as safe.

Potential concerns include unintended gene-regulatory effects, immune reactions, developmental effects and impurities in poorly controlled material. Long-term carcinogenicity, reproductive toxicity, medicine interactions and organ-specific toxicity have not been adequately characterised publicly.

Is Pinealon approved?

Pinealon is not approved by the United States Food and Drug Administration, the United Kingdom Medicines and Healthcare products Regulatory Agency or the European Medicines Agency. No authorised product label or regulator-reviewed indication exists in those jurisdictions.

Use or publication in Russia does not establish approval elsewhere. A named commercial preparation is not the same as a medicine supported by modern confirmatory evidence.

How strong is the evidence overall?

QuestionBest available evidenceDefensible conclusion
Does EDR interact with cells and DNA?Cell uptake and purified-DNA experimentsLaboratory interaction is supported; in-vivo specificity is uncertain
Does it alter oxidative-stress markers?Several cell and rodent studiesSelected markers changed under experimental stress
Does it affect learning or neuronal structure?Rodent tests and disease-model neuronal culturesPreclinical signals exist; clinical benefit is not established
Has it been given to people?Small, incompletely reported Russian studiesHuman exposure is reported, but evidence quality is low
Does it treat brain injury or dementia?No confirmatory controlled trialNot established
Does it slow human ageing?Small mixed study using surrogate measuresNot established
Is it approved by FDA, MHRA or EMA?No approvalNo

Pinealon has a broader publication record than many online research peptides, but much of it is mechanistic, small, difficult to appraise and produced by one research school. Volume of claims does not replace rigorous independent trials.

What claims are not established?

Pinealon has not been shown to prevent Alzheimer's disease, repair traumatic brain injury, restore memory, increase intelligence, extend lifespan, reverse ageing or protect a healthy human brain from stress.

It has no evidence-based self-administration protocol. There is no controlled evidence that combining it with Epitalon, Semax, Selank, Vesugen or other bioregulator peptides improves outcomes or reduces risk.

FREQUENTLY ASKED QUESTIONS

Frequently asked questions

What is Pinealon made of?

It is a tripeptide containing glutamic acid, aspartic acid and arginine, abbreviated EDR.

Is Pinealon a pineal-gland hormone?

No. Its name does not make it a natural pineal hormone, and synthetic EDR is a defined three-residue peptide.

Is Pinealon the same as Epitalon?

No. Pinealon is Glu-Asp-Arg. Epitalon is Ala-Glu-Asp-Gly.

Is Pinealon the same as Cortexin?

No. Cortexin is an animal-tissue-derived peptide mixture, while Pinealon is one defined synthetic sequence.

Does Pinealon bind DNA?

Interaction with purified DNA has been reported in biophysical experiments. The clinical meaning and selectivity of that interaction are unknown.

Does Pinealon improve memory?

Rodent studies and small human reports describe memory-related findings, but no adequate confirmatory trial establishes a memory benefit.

Does Pinealon treat Alzheimer's disease?

No. Cell and pathway research has not demonstrated treatment or prevention in people.

Has Pinealon been tested in humans?

Small Russian studies report human exposure, including groups with brain-injury consequences and chronic conditions. Their design and reporting do not establish efficacy or comprehensive safety.

Is Pinealon known to be safe?

No. The available human reports are too small and incomplete to define short-term or long-term risk reliably.

Is Pinealon approved?

It is not approved by the FDA, MHRA or EMA for any indication.

Research reviewed through October 2026.